A more complex clinical trial was used for the treatment of colorectal cancer, triple-negative breast cancer, NSCLC and adenocarcinoma, where the anti-PD-1 mAb PDR001 (13) was used in combination with either (i) the anti-interleukin-1 beta (IL-1b) mAb canakinumab (214), (ii) the anti-IL-17 mAb CJM112 (219), (iii) the small molecule inhibitor trametinib (MAPKK1 and MAPKK2 inhibitor) or (iv) the EGFR antagonist nazartinib (NCT02900664). Here, IL1B is linked to adenocarcinoma.